Saxena AR, Frias JP, Gorman DN, Lopez RN, et al. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes. Diabetes Obes Metab 2023 Jun 13. doi: 10.1111/dom.15168.
PMID: 37311722